

Trobix Bio Announces Renowned Clinicians and Scientists to Join its Scientific Advisory Board

Netanya, Israel, November 10, 2021

Netanya, Israel. Trobix Innovation Ltd. ([Trobix Bio](#)), an Israeli based biotechnology company, developing novel microbiome-based therapeutics to treat severe unmet needs, announces that a group of renowned clinicians and scientists are joining its advisory board. Prof. David Hooper, Prof. Alex Lepak and Dr. David Pompliano will be joining current board members Prof. Udi Qimron and Prof. Itamar Shalit. This eminent group of scientists and clinicians will bring cutting-edge expertise to Trobix Bio as the company expands the utility of its innovative platform, to develop microbiome-based therapeutics in high unmet need sectors such as oncology, immune modulation, antimicrobial resistance and more.

“It is truly an honor to announce these distinguished and prominent experts as new members of Trobix Bio Scientific Advisory Board”, said Dr. Adi Elkeles, Founder & CEO of Trobix Bio. “The combined knowledge of our SAB members in translational science and clinical development as well as their strategic counsel will serve as a vital resource in advancing the development of our product pipeline to address multiple areas of high unmet need”, he added.

Trobix Bio SAB members include:

Professor David Hooper

Professor David Hooper is a Professor of Medicine at Harvard Medical School, and the Chief of the Infection Control Unit and Associate Chief of the Division of Infectious Diseases at the Massachusetts General Hospital. He is also former Director of the Antimicrobial Stewardship Program at MGH.

Prof. Hooper’s research has focused on mechanisms of antimicrobial action and resistance. His laboratory has received continuous funding from the NIH for the past 30 years, and he is a recipient of an NIH Merit Award. He is author of over 200 peer-reviewed articles on mechanisms and epidemiology of antimicrobial resistance and 76 book chapters and other articles. Dr. Hooper is a Fellow of the American Academy of Microbiology and the Infectious Diseases Society of America and a Member of the Association of American Physicians. In 2016 he received the Antimicrobial Research Award from the American Society for Microbiology (ASM). He has served as Chair of the Drug Discovery and Antimicrobial Resistance Study Section of the NIH and Chair of the Scientific Program Committee of the Interscience Conference on Antimicrobial Agents and Chemotherapy of the ASM. He is past President and past Meetings Board Chair of the ASM, has served on the editorial board of Antimicrobial Agents and Chemotherapy, and is Deputy Editor of The Journal of Infectious Diseases.

Professor Alex Lepak

Professor Alex Lepak is an associate Professor at the University of Wisconsin. Prof. Lepak is an active physician, educator, researcher, and leader of antimicrobial stewardship. His research

pursuits are in performing and translating antimicrobial pharmacodynamic (PD) studies (both in vivo animal models and patient level data) to optimize therapy against numerous pathogens. Specifically, this research has included medically important fungal and bacterial pathogens, including those that are difficult to treat and/or have drug resistance determinants. An additional area of active study is antimicrobial drug development using in vivo animal models. His lab has evaluated hundreds of pre-clinical and clinical compounds and is internationally recognized for drug development and drug optimization via PK/PD approaches. Dr. Lepak's studies have been internationally recognized with numerous invited presentations and over 130 publications and presentations at meetings.

Clinically, he attends regularly on all infectious disease consult services and is the director of antimicrobial stewardship at UWHealth. He leads quality improvement and research projects focused on improving antimicrobial and diagnostic test utilization. Based on his expertise in PK/PD and stewardship, he is a leader in GNR resistance mechanisms and treatment strategies. His leadership and expertise have led to national and international recognition and invitations to provide guidance for numerous groups including: USCAST, CLSI, GARDP-REVIVE, ICAAC, ECCMID, ASM, IDSA, and the US FDA.

Dr. David Pompliano

Dr. David Pompliano is a drug discovery scientist, entrepreneur and executive with 30 years of experience in the biopharmaceutical industry. Dr. Pompliano co-founded, and served as CSO of, Revolution Medicines (RVMD, a Third Rock company) and Lodo Therapeutics (an Accelerator company acquired by Zymergen, ZY), co-founded and is CEO of Daros, was co-founder and CEO of BioLeap, and raised over \$70m in Series A financing. He also serves on the Boards of Directors and Scientific Advisory Boards of several biotechnology companies, government agencies and philanthropies.

Earlier, as a senior pharmaceutical executive at GlaxoSmithKline and Merck, he led drug discovery teams that produced pre-clinical credentials for >30 development candidates and five registered anti-infective (Recarbrio, Altabax) and oncology (Tykerb, Votrient, Promacta) drugs. As Principal and Owner at Sanderling Consulting LLC, he assists investors, companies, and philanthropies in setting drug discovery strategy, in executing the operations of preclinical discovery and development, and in evaluating pharmaceutical assets. Dr. Pompliano earned the BS and Ph.D degrees in Chemistry from the University of Virginia and from Stanford University, respectively, and conducted research in enzymology and molecular biology as a National Institutes of Health Postdoctoral Fellow in Jeremy Knowles' laboratory at Harvard University. He has published more than 50 peer-reviewed papers in the areas of infectious diseases and cancer drug discovery and mechanistic enzymology and has presented over 50 invited lectures internationally."

Professor Udi Qimron

Professor Qimron is a professor of Clinical Microbiology at Tel-Aviv University, Israel. As an Independent Principal Investigator at Tel Aviv University for over 10 years, Prof. Qimron led one of the most productive labs in the Faculty of Medicine. He won the "Best Publication Award" consecutively three times in a row since the establishment of the prize in 2015. Furthermore, Udi's lab has published over 30 scientific papers, many of which are in top tier

journals such as Nature, Nature Microbiology, PNAS and more. The European Research Council recognized his excellence by awarding him an ERC Starting Grant, an ERC Consolidator Grant and an ERC PoC Grant.

Prof. Qimron is recognized as a leading expert in the CRISPR-Cas field, particularly as an expert in the adaptation step of the bacterial immune system. As such, he has reviewed dozens of articles in recent years for top journals and has been invited as a guest and speaker to numerous top conferences in the field.

Professor Itamar Shalit

Professor Itamar Shalit is an Associate Professor (retired) in Pediatrics, Sackler School of Medicine, Tel-Aviv University and a leading authority in Pediatric Infectious Diseases. Prof. Shalit served as the Director of the Infectious Diseases Unit and Director General of Schneider Children`s Hospital, tertiary care, referral pediatric center for the entire State of Israel. He also served as the Director General of the Carmel Hospital and the Chairman of the Israeli Society for Infectious Diseases. In addition, he served as a member of the Scientific Advisory Boards of leading pharma and biotech companies including Bioline Rx, Teva Innovative Ventures, NasVax and Integra Ltd. Itamar is currently serving as an active member on several national committees at the Israeli Ministry of Health including the Advisory Board on Infectious Diseases and Immunization; the National Committee on Measles, Mumps and Rubella Eradication; and the Polio Eradication Committee. He was awarded the Certificate of Appreciation Declaration by the World Health Organization for outstanding efforts and success in poliomyelitis eradication in Israel.

Itamar is an author of more than 90 peer reviewed scientific publications and holds an MD degree from the Sackler School of Medicine, Tel-Aviv University and an MPA (Master in Public Administration) from the Kennedy School of Government, Harvard University, USA.

About Trobix Bio

Trobix Bio vision is to harness the power of microbiome to develop life-changing therapeutics by empowering engineered bacteriophages with CRISPR to develop precision microbiome-based therapeutics that address huge unmet needs in major medical therapeutic areas such as oncology, immune modulation and antimicrobial resistance.

For more information, please contact:

Dr. Adi Elkeles

Founder & CEO

Trobix Bio

Tel: +972-54-6402333

Email: adie@trobox.bio